All pembrolizumab articles
-
NewsMicrobiotica announces completion of recruitment in its international phase 1b trial of microbiome co-therapy
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is complete in its advanced melanoma (MELODY-1) trial.
-
NewsStudy reveals how bacteria in microbiome medicine trigger tumor-killing cells
Microbiotica has presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma.
-
NewsVirus aids breakthrough in glioblastoma treatment
Scientists have reported a breakthrough in glioblastoma treatment following a recent clinical trial that used a modified cold virus injected directly into the tumor.